Zenocutuzumab

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

Journal: International journal of molecular sciences
Published: April 08, 2026

Advances in the clinical application of bispecific antibodies in cancer therapy.

Advances in the clinical application of bispecific antibodies in cancer therapy.

Journal: iScience
Published: January 01, 2026

KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

Journal: Cancers
Published: October 29, 2025

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.

Journal: Journal of the National Cancer Institute
Published: October 13, 2025

COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling.

COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling.

Journal: Clinical and molecular hepatology
Published: September 26, 2025

Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.

Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.

Journal: European journal of medical research
Published: September 16, 2025

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment.

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment.

Journal: Oncology (Williston Park, N.Y.)
Published: August 20, 2025

Actionable mutations in pancreatic cancer: where targeted therapies are making a difference.

Actionable mutations in pancreatic cancer: where targeted therapies are making a difference.

Journal: BMJ open gastroenterology
Published: May 28, 2025

Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration.

Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 21, 2025

Targeting Tumor Microenvironment-Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer.

Targeting Tumor Microenvironment-Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer.

Journal: Molecular cancer therapeutics
Published: May 05, 2025

Emerging importance of HER3 in tumorigenesis and cancer therapy.

Emerging importance of HER3 in tumorigenesis and cancer therapy.

Journal: Nature reviews. Clinical oncology
Published: February 24, 2025

Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours.

Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours.

Journal: Nature reviews. Clinical oncology
Published: February 20, 2025
Showing 1-12 of 30

Last Updated: 06/30/2026